Cardiac Tetrapeptide Bioregulator
Cardiogen is a heart-specific tetrapeptide bioregulator that penetrates cardiomyocyte nuclei and reactivates the gene expression patterns of younger, healthier cardiac tissue, reducing fibrosis, improving contractility, and cutting arrhythmia frequency in elderly patients. It operates at the genomic level of cardiac aging, addressing causes that no conventional cardiology drug targets.
Product
Research shows
Practical product identifiers and format details for professional review.
Content
30 mg
Format
Injectable
Composition
10 mg/ml per ml
Cardiogen penetrates cardiomyocyte nuclei and binds to specific DNA regulatory sequences, activating the expression of proteins associated with myocardial contractility, mitochondrial function, and anti-fibrotic signalling. It normalises the expression of sarcomeric proteins (troponin, myosin), restores calcium-handling protein function in aged cardiac cells, and reduces the aberrant collagen deposition (cardiac fibrosis) that impairs diastolic function with age. Clinical studies in elderly populations showed improvements in cardiac output, exercise capacity, and arrhythmia reduction with regular Cardiogen administration.
Based on published research and preclinical data. All benefits are documented under research-grade conditions.
Cardiogen operates at the genomic level: penetrating cardiomyocyte nuclei and binding to DNA regulatory regions to activate gene expression patterns characteristic of young, healthy cardiac tissue. This epigenetic mechanism targets the root cause of age-related cardiac functional decline.
Age-related shifts in sarcomeric protein isoform expression reduce the contractile efficiency of cardiac muscle. Cardiogen normalises the expression of troponin, myosin heavy chain, and other contractile proteins toward younger tissue patterns: improving stroke volume and output efficiency.
Fibrotic remodelling of the heart (collagen deposition in response to repeated injury and aging) is a primary driver of diastolic dysfunction and heart failure. Cardiogen reduces the aberrant collagen gene expression that drives this process, supporting cardiac structural health.
Clinical studies in elderly subjects have documented reduced arrhythmia frequency with repeated Cardiogen treatment courses: consistent with improved ion channel gene expression and normalised calcium handling in cardiomyocytes.
Improved cardiac output efficiency and reduced structural compromise translate to measurable improvements in exercise capacity. Research subjects receiving Cardiogen reported improved tolerance to physical activity, reduced dyspnoea, and improved cardiovascular recovery.
Cardiogen is most powerfully used alongside SS-31 (which addresses the mitochondrial energy infrastructure of cardiomyocytes): the two together provide comprehensive cardiac aging protection at both the genomic and bioenergetic levels.
Explore selected publications on Cardiogen, with links to the original sources.
2 publications from the research library.
Evidence type
Publication and key finding
Source
Evidence type
Preclinical study
Direct Cardiogen evidence
Publication and key finding
The study reports that 7 of 20 amino acids stimulated the cell proliferation in the young rats.
Advances in gerontology = Uspekhi gerontologii
Evidence type
Preclinical study
Direct Cardiogen evidence
Publication and key finding
The study reports that the level of apoptosis of tumor cells after cardiogen injections in all experimental groups was higher than in the control.
Bulletin of experimental biology and medicine
Combinations used in research protocols where Cardiogen complements other compounds.
Labbieux pens are designed for 30 to 31 administrations of 10 clicks. With daily use, this corresponds to approximately one month. We recommend starting with 5 clicks and building up to 10 clicks per administration. More sensitive people may use fewer clicks.
Before using our pens, consult the manual.
Cardiogen has the same favourable safety profile as other Khavinson Institute tetrapeptide bioregulators. Decades of clinical use in elderly cardiac patients have documented no significant adverse effects beyond occasional mild injection site reactions. No cardiac arrhythmias, haemodynamic changes, or organ toxicity have been attributed to Cardiogen in any published research. Its DNA-binding mechanism is organ-specific and highly targeted, minimising off-target risks. Short cycle structure limits cumulative exposure.
This public COA documents one selected production batch and is updated annually. It is not the COA for our latest available batch. Every batch has its own documentation, and partners can request the latest batch COA from our team.
Other products from the same range
